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Abstract
We have developed a high-density microarray platform consisting of nano-biofilms of Candida albicans. A robotic
microarrayer was used to print yeast cells of C. albicans encapsulated in a collagen matrix at a volume as low as 50 nL onto
surface-modified microscope slides. Upon incubation, the cells grow into fully formed ‘‘nano-biofilms’’. The morphological
and architectural complexity of these biofilms were evaluated by scanning electron and confocal scanning laser microscopy.
The extent of biofilm formation was determined using a microarray scanner from changes in fluorescence intensities due to
FUN 1 metabolic processing. This staining technique was also adapted for antifungal susceptibility testing, which
demonstrated that, similar to regular biofilms, cells within the on-chip biofilms displayed elevated levels of resistance
against antifungal agents (fluconazole and amphotericin B). Thus, results from structural analyses and antifungal
susceptibility testing indicated that despite miniaturization, these biofilms display the typical phenotypic properties
associated with the biofilm mode of growth. In its final format, the C. albicans biofilm chip (CaBChip) is composed of 768
equivalent and spatially distinct nano-biofilms on a single slide; multiple chips can be printed and processed
simultaneously. Compared to current methods for the formation of microbial biofilms, namely the 96-well microtiter
plate model, this fungal biofilm chip has advantages in terms of miniaturization and automation, which combine to cut
reagent use and analysis time, minimize labor intensive steps, and dramatically reduce assay costs. Such a chip should
accelerate the antifungal drug discovery process by enabling rapid, convenient and inexpensive screening of hundreds-to-
thousands of compounds simultaneously.
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Introduction
Candida albicans is the main causative agent of candidiasis, the
most common fungal infection and now the third to fourth leading
nosocomial infection in US hospitals [1,2]. These infections have
emerged as a growing threat to human health, especially for an
increasing number of immunocompromised individuals who are at
risk for opportunistic infections. The high mortality rate associated
with candidiasis is in part due to the limited arsenal of antifungal
drugs [3,4,5]. Another major reason is because candidiasis is
frequently associated with biofilm formation on both inert and
biological surfaces, and cells within these biofilms are intrinsically
resistant to most antifungal agents and host defenses [6,7]. Indeed,
the increase in Candida infections in the last decades has almost
directly paralleled the increase and widespread use of a broad
range of medical implant devices [6,7,8,9].
Biofilms are complex microbial communities, attached to a
surface and typically encased within an exopolymeric material or
matrix [10,11,12]. In the case of C. albicans, biofilms are composed
of different morphological forms of the organism including yeast,
pseudohyphae and hyphae, encased within an extracellular matrix
[13,14]. The antifungal resistance of biofilms is primarily
attributed to increase in cell number and changes in genetic,
physiological and molecular characteristics of the cells in the
biofilm, and secondarily to slow diffusion of drugs, and/or binding
of drugs to the biofilm matrix [15,16,17,18,19,20]. Thus, there is a
need to develop new strategies for the screening and discovery of
antifungal drugs that prevent or control the formation of biofilms
[21]. Although there are many different models for the formation
of C. albicans biofilms in vitro; from the point of view of antifungal
susceptibility testing, perhaps the most useful is the 96-well
microtiter plate model [22,23]. However, in the search for new
and improved therapeutics, a field now dominated by high
throughput screenings and hunger for speed, practical consider-
ations of time, cost and efficiency severely limit the use of 96-well
plate assays for probing diverse set of chemical libraries containing
tens of thousands of molecules for new drugs; and novel, improved
technologies are sorely needed.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19036Here we describe the development of a high-throughput
microarray based technology for the formation of fungal biofilms.
We present a C. albicans biofilm chip, or CaBChip, that employs C.
albicans, the main causative agent of candidiasis and the most
common fungal infection. In its present format, CaBChip consists
of 768 spatially distinct and equivalent nano-biofilms, each with a
volume of few tens of nanoliters, on a standard 10630 glass slide.
We expect these chips to accelerate the antifungal drug discovery
process by enabling rapid, convenient and inexpensive screening
of hundreds-to-thousands of compounds simultaneously.
Materials and Methods
Strain and culture conditions
C. albicans strain SC5314, a well characterized strain from the
point of view of biofilm formation [22,23,24], was used throughout
the study. Cells stored at 270uC as glycerol stocks were
propagated by streaking a loopful of cells onto yeast peptone
dextrose (YPD) agar (1% [wt/vol] yeast extract, 2% [wt/vol]
peptone, 2% [wt/vol] dextrose) and incubated overnight at 37uC.
A loopful of cells from YPD agar plates were inoculated into flasks
(150 ml) containing 20 ml of YPD liquid media to be grown
overnight in an orbital shaker (150–180 rpm) at 30uC. Under
these conditions, C. albicans grows as budding-yeasts.
Preparation of Functionalized Slides
Normal microscopic glass slides (10630) (Fisher Scientific,
Waltham, MA) were cleaned extensively to expose the silanol
groups (-SiOH) on the surface. First, the slides were placed in a
removable slide rack and washed by immersing them in a staining
jar containing ethanol. The slides were then wiped clean using
paper towels and air-dried using nitrogen gas. Next, the slide rack
containing the slides was immersed in a dish filled with
concentrated sulphuric acid and incubated for an overnight
treatment. Finally, these slides were subjected to sonication and
washed with Milli-Q water for 30 min, following another wash in
acetone. This treatment exposed the silanol groups on the glass
surface.
Clean slides were then coated with 3-aminopropyltriethoxysi-
lane (APTES) (Sigma Aldrich, St. Louis, MO), by immersing the
slide rack in APTES for 30 min. The slides were baked in the
furnace at 110uC for 15 min. Baking allowed cross-linking of the
APTES, resulting in glass slides with its surface expressing
functional groups (-NH2-) of APTES. Finally the slides were spin
coated with 1% (wt/vol in toluene) Polystyrene-Co-Maleic
Anhydride (PS-MA) (Sigma) to achieve a mono-layer of hydro-
phobic coating.
Optimization and printing of high density fungal cell
arrays onto functionalized glass slides and subsequent
biofilm development
A four-factor, two-level factorial design was performed using
MINITAB (Minitab Solutions Inc., State College, PA) and
DESIGN EXPERT (Stat-Ease Inc., Minneapolis, MN) software
to obtain optimal conditions of media concentration, seeding
density, collagen concentration and PSMA coating concentration
for wash-resistant biofilm growth on the CaBChip (Methods S1).
The response (output) metrics were true biofilm yield and robust
attachment, measured using microarray scanner and light
microscope (Figure S1 and S2). For preparation of inocula for
printing and biofilm formation in the CaBChip, cells harvested
from overnight YPD cultures were washed twice in sterile
phosphate buffered saline (PBS; 10 mM phosphate buffer,
2.7 mM potassium chloride, 137 mM sodium chloride (pH 7.4)
(Sigma) by centrifugation at 3000g. The cells were then
resuspended in Reconstruction buffer (0.2N NaOH solution with
2.2% (wt/vol) Sodium Bicarbonate and 4.8% (wt/vol) HEPES).
One hundred fold dilutions of the suspended cells were prepared
and counted using a hemocytometer on a bright field microscope.
Following count, a suspension of cells was prepared in
reconstruction buffer at a cell density of 5610
7 cells/mL, which
was diluted ten times by addition of 106 RPMI-1640
supplemented with L-glutamine and buffered with morpholine-
propanesulfonic acid (Angus Buffers and Chemicals, Niagara
Falls, NY) containing collagen (1.8 mg/ml) (Type 1 from rat tail,
BD Biosciences, Bedford, MA), to give a final concentration of
cells of 4610
6 cells/mL. The suspension containing yeast cells,
collagen and media was printed (50 nL per spot) on the
functionalized PSMA-coated glass slides using a microarray
spotter (Omnigrid Micro, Digilab Inc., Holliston, MA). Printing
was carried out by non-contact deposition using conically tapered
190 mm orifice ceramic tips (Digilab). The resulting spots were
approximately 700 mm in diameter, spaced 1.2 mm apart; spots
were printed in an array of 48 rows and 16 columns. In a
standard print run, the tips were primed, rinsed in running water
and vacuum dried twice after each loading and printing step, The
cell suspension was kept on ice to prevent the gelation of collagen
before printing and agitated gently just prior to placement on the
printing robot to ensure a uniformly mixed cell suspension. A
relative humidity of 97% was maintained during printing to
prevent the drying of the biofilm spots. All microarray operations
such as aspiration, dispensing, priming, printing and spatial
distribution of array were controlled by AxSys program (Digilab).
All surfaces, including the source plate station, wash and vacuum
station, vacuum slide platter and printing chamber were sterilized
by wiping with 70% isopropanol. In our experience, these
procedures ensure that there is no detectable contamination of
wells in the plates or of spots on the microarray. Immediately
after printing, the slides were placed inside humidifier chambers
(ArrayIt Corporation, Sunnyvale, CA) which were placed inside a
37uC incubator over different periods of time to allow for biofilm
formation.
Assessment of metabolic status of cells within biofilms
FUN 1 [2-chloro-4-(2,3-dihydro-3-methyl-(benzo-1,3-thiazol-2-
yl)-methylidene)-1–phenylquinolinium iodide] (Invitrogen Corp.,
Carlsbad, CA) was used to stain and determine viability (levels of
metabolic activity) of C. albicans cells within the biofilms formed in
the chips. This membrane-permeable fluorescent dye is internal-
ized and processed by metabolically active fungal cells, and has
excitation and emission spectra that are compatible with the sets of
lasers and filters installed in most microarray scanners. Briefly, the
CaBChip was stained with 0.5 mM FUN 1, by simply dunking the
entire CaBChip in a staining jar, and incubated in the dark at
37uC for 30 min. Following incubation, the chip was washed three
times by dunking in PBS in order to remove excess stain. The
slides were then air-dried and scanned in a microarray scanner
(Genepix Personal 4100A, Axon Instruments, Union City, CA). A
laser of 532 nm with a PMT gain of 270 was used to read the chip
and fluorescent intensity of each spot was determined using
GenePix 4.1 software (Axon). Fluorescence levels from FUN 1
staining were recorded as Relative Fluorescence Units (RFU). The
microarray reader converts the real fluorescence signal into an
electronic signal that can be ‘‘tuned’’ using the gain setting or
sensitivity setting, and thus RFU is an arbitrary unit. Initial
experiments indicated an excellent linear correlation between
number of metabolically active cells spotted on the microarray and
levels of FUN 1 fluorescence (Figure 4A).
High-Throughput Biofilm Chip
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Bright-field light microscopy techniques on an inverted
microscope (Fisher Scientific) equipped for photography were
used to routinely monitor biofilm formation, as a means of directly
visualizing the overall morphology, distribution and topography of
biofilms grown in the chip. The images were processed for display
using Micron software (Westover Scientific, Bothell, WA). For
scanning electron microscopy, biofilms formed in the chip were
fixed with a solution of glutaraldehyde (2.5% w/v) in 0.1 M
sodium cacodylate buffer at pH 7.4 for 2 h at 37uC. Following
fixation the biofilms were treated with a solution of osmium
tetraoxide (1% w/v) in 0.1 M sodium cacodylate buffer at pH 7.4
for 2 h at room temperature. The samples were rinsed with water
and soaked in a series of ethanol solutions (a step gradient of 30%,
50%, 70%, and 90% in water for 10 min per step), ending with
100% ethanol. After dehydration, the samples were dried
overnight in a vacuum dryer and subsequently coated with a
60:40 gold-palladium alloy; approximately 10 nm thick using a
Cressington Sputter coater for a duration of 30 sec. Scanning
electron microscopy was performed using a Zeiss EVO 40 electron
microscope (Carl Zeiss, Thronwood, NY). Confocal Scanning
Laser Microscopy (CSLM) of FUN 1 stained biofilms to visualize
three dimensional patterns and determine the architecture of the
biofilms grown in the chip. CSLM was performed with a Zeiss
LSM 510 confocal microscope (Carl Zeiss), using a rhodamine/
fluorescein isothiocyanate protocol with excitation at 488 nm
(argon ion laser). Images of sections in the xy plane were taken
along the z axis, acquired by the resident software and processed
using AutoQuant (Media Cybernetics, Bethesda, MD) and
IMARIS 6.4 (Bitplane, St. Paul, MN).
Susceptibility testing of cells within preformed C.
albicans biofilms in CaBChip against antifungal agents
Susceptibility testing of cells within C. albicans biofilms in
CaBChip was performed against clinically used antifungal agents
amphotericin B and fluconazole. Amphotericin B was obtained as
a powder from Sigma (St. Louis, MO). A stock solution of
Amphotericin B (1.6 mg/ml) was prepared in DMSO and stored
at 220uC until used. Fluconazole was obtained as injection from
Sicor Pharmaceuticals, Inc. (Irvine, CA). A stock solution of
Fluconazole in 0.9% Sodium Chloride solution, available as
injection was stored at 4uC until used. Subsequent dilutions of the
antifungals were made in RPMI-1640 media supplemented with
L-glutamine and buffered with MOPS. On top of the biofilms
formed after 24 h, drugs of desired concentration of equal spot
volume (50 nL), in two-fold dilutions were spotted using the
robotic microarrayer. The CaBChip(-s) containing drugs were then
incubated in a humidified chamber for an additional 24 h, after
which the slides were washed by gently dunking them in PBS. The
CaBChips were then stained with 0.5 mM FUN1 and the
metabolic activity of cells within biofilms were read using the
microarray scanner. Eight different concentrations of the drugs in
six replicates, with appropriate positive (no drug) and negative
(dead cells) controls were tested on a single CaBChip. Multiple (at
least two) chips were processed in parallel. Thus, depending upon
the efficacy of the drug and its dose, each spot had different
fluorescence levels and by quantifying these values at each spot,
susceptibility profiles for each compound were determined. The
fluorescence intensity of the control and dead (killed with sodium
hypochlorite for 20 min) biofilms were arbitrarily set at 100% and
0% respectively, and the inhibitory effects of compounds were
determined by the reduction in fluorescence intensity in relation to
the controls, as measured in the microarray scanner. Data was
calculated and expressed as percent biofilm inhibition relative to
the average of the control wells. SMIC50 and SMIC80 values for
each antifungal were determined as before [22,23]. The calculated
IC50 (Inhibitory Concentration of drugs required to reduce the
fluorescence intensity by half, compared to live –controls) values
were determined by fitting the variable slope Hill equation (an
equation determining the non-linear drug dose-response relation-
ship) using GraphPad Prism software (La Jolla, CA). For
comparison purposes, antifungal susceptibility testing was also
performed using the 96-well microtiter plate model of C. albicans
biofilm formation previously developed by our group [22,23], that
uses the colorimetric (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-
2H-tetrazolium-5-carboxanilide) (XTT) assay as a measure of
viability of cells within biofilms (see also Figure S3 and Table S1).
Results and Discussion
Traditionally, most models for the formation of C. albicans
biofilms are cumbersome, requiring expert handling, large
volumes, long processing times and the use of specialized
equipment not generally available in a regular microbiology
laboratory. Frequently biofilms are grown on catheter disks or
sheets placed inside a fermentor or a bioreactor under either static
or dynamic flow conditions [14]. These culture techniques are
slow, complex and demanding, and were mitigated to a great
extent by the development of a 96-well microtiter plate model for
the formation of C. albicans biofilms [22,23]. In this model, fungal
biofilms are formed on the bottom of the wells of microtiter plates,
and the ability of metabolically active sessile cells to reduce a
tetrazolium salt (XTT) to water-soluble orange formazan com-
pounds, the intensity of which can then be determined using a
microtiter-plate reader, is used as a semi-quantitative measure-
ment of biofilm formation. This model was also adapted for
antifungal susceptibility testing of cells within the biofilms [22,23].
However, in this era dominated by high throughput demands and
‘‘hunger for speed’’, the multiwell plate format still suffers from
several limitations, most importantly inefficient liquid handling
and removal without disturbing the biofilms, which severely limits
the automation of this process. Other disadvantages of 96-well
microtiter plate model include the need for relatively larger
volume of reagents (thereby increasing costs) as well as
incompatibility with high content experimentation and image
analysis. A microarray format/platform ameliorates all these
issues, thus allowing for truly high-throughput applications.
Though the microarrays have been used to great benefit in the
fields of genomics and proteomics, comparatively little effort has
been directed toward using cellular microarrays, particularly in the
case of pathogenic microorganisms [25,26,27,28,29,30,31].
Design and Fabrication of the Candida albicans Biofilm
Chip (CaBChip)
Our objective was to develop a high density microarray of
spatially addressable three-dimensional biofilms of C. albicans,
which should satisfy the following requirements: (i) firmly hold
hundreds of spatially distinct biofilms on a single glass slide; (ii)
forms a ‘true’ biofilm, and though small, displays phenotypic
properties comparable to those of regularly-grown biofilms (i.e.
growth, morphological and architectural characteristics and
increased drug resistance); (iii) does not dry easily so that the cells
may be cultured for prolonged periods of time; (iv) attaches
robustly to the substrate and does not detach against multiple
washings; and (v) fully compatible for analysis with a standard
microarray scanner. We first performed a series of proof-of-
concept experiments, mostly using manual pipetting prototypes, to
check multiple parameters of biofilm formation, including those
High-Throughput Biofilm Chip
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and inocula preparation. The first requirement was that of a
hydrophobic surface, allowing for discrete, independent liquid
spots of small volume (in the nanoliters range) to be deposited on
the surface of the microscope slide. Thus, the borosilicate (glass)
slides were first pre-treated with 3-aminopropyltriethoxysilane
(APTES), followed by coating with polystyrene-co-maleic anhy-
dride (PSMA) (Figure 1A). The styrene-co-maleic anhydride
molecules zip together forming a mono-layer made of two
molecules in cross section, thus enhancing the hydrophobicity of
the substrate [32]. The PSMA also provides sufficient functionality
for subsequent binding to an encapsulating matrix such as collagen
[31,33]. The use of an encapsulating matrix was deemed necessary
since initial experiments indicated that, in order to form robust
(capable of withstanding the multiple washing steps) C. albicans
biofilms on the microscope slides, it was required to encapsulate
the fungal cells within a matrix. The use of collagen as the matrix
of choice was mostly due to its optimal and easily controllable
gelation characteristics, strong electrostatic/covalent binding to
the functionalized surface, and the fact that it represents a
biological substrate that mimics the tissue extracellular matrix in
vivo. However, we also note that collagen encapsulation may limit
the utility of the chip for the identification of compounds that
affect early adherence or the biofilm matrix, as well as negatively
influence the antifungal activity of compounds that bind protein
with high avidity.
Next, using a two-level factorial design, we found the optimal
operating parameters namely, concentrations of collagen, PSMA,
C. albicans seeding density and growth media, that maximized the
biofilm yield on spots that are stably attached to the substrate
(Figure 1B). We observed that (i) high collagen concentration did
not favor filamentation, and cells remained in planktonic form;
and, on the other hand, low collagen concentration did not favor
robust attachment of spots; (ii) excessively rich media resulted in
hyper-filamentation forming a pseudo-biofilm, and poor media did
not promote sufficient cell growth; (iii) high seeding density did not
favor biofilm formation; and (iv) high PSMA coating concentra-
tion promoted stable attachment of spots. Hence, we concluded
that a collagen concentration of 1.8 mg/ml with cell seeding
density 4610
6 cells/ml in a 46 RPMI media printed on 0.1%
PSMA-coated surfaces will yield most optimal biofilm chip (Figure
S1 and S2). Finally, we printed the high density arrays using a
robotic microarrayer. We robotically spotted a total of 768 spots of
50 nL each, containing a suspension of C. albicans yeast cells in
collagen and microbiological media. This resulted in hemispher-
ical spots that were 700 mm in diameter, with a spot-to-spot
distance of 1.2 mm. After initial printing, the slides are simply
incubated under inside humidifying chambers (to prevent drying)
at 37uC to allow for biofilm development (Figure 1C). No
additional media was added to the biofilm chip after initial
spotting, which is in stark contrast with most models in which
biofilms are submerged in large volumes of media. The extent of
biofilm formation was assessed using FUN 1, a simple and sensitive
assay for fluorescent staining of metabolically active fungal cells,
which is fully compatible with standard microarray scanners.
Growth characteristics and morphological and
architectural features of C. albicans biofilms in the
CaBChip
By using conventional methods for C. albicans biofilm formation,
it is well established that the process of biofilm development occurs
through different phases, including initial adherence of cells to a
substrate, followed by growth and proliferation (which in the case
of C. albicans is intimately associated with filamentation), and a
final maturation phase that also includes accumulation of the
extracellular matrix [13,34]. To further establish the kinetics of
biofilm formation in the chip format, we monitored the growth of
viable cells in collagen gel spots on the CaBChip over time using
both microscopy and FUN 1 staining. This fluorescent dye is
processed biochemically in the cytoplasm of living cells, forming
cylindrical intravacuolar structures and rendering a fluorescent
signal that can be read with a regular microarray reader using the
appropriate excitation and emission filters. Similar to regular
biofilms, direct bright-field microscopic observations revealed that
C. albicans biofilms formed in the CaBChip are composed of yeast,
pseudohyphae and hyphae (Figure 2A). The results from these
series of experiments indicated that, after a somewhat extended lag
time of about 4 hours, cells grew rapidly and developed biofilms
with maximum readings observed at approximately 12–18 h for
what seem to be fully developed, complex biofilms. After 18 h,
there was a reduction in the metabolic activity of biofilm cells, thus
indicating that biofilms had reached maturity (Figure 2B). Thus, it
would seem that, compared to other standard methods in which
formation of mature biofilms typically occurs over 24–48 h and
beyond [13,34,35], the process of biofilm development and
maturation is somewhat accelerated in the chip, most likely due
to the sub-microliter volume range, which in turn may result in
faster nutrient depletion and accumulation of metabolic waste.
In order to further ascertain the morphological and architec-
tural characteristics of biofilms in the CaBChip, we used SEM and
CSLM. SEM provides a visual description of the biofilms at higher
magnification. Shown in Figure 3A are a series of close-up images
of spots in the biofilm chip with increasing magnification. At the
highest magnification it can be seen that the fungal hyphae are
embedded within the matrix of collagen fibers, which are
approximately 2 mm and 100 nm in diameter, respectively.
Contrary to SEM, the non-destructive nature of CSLM allows
for the visualization of biofilms in its native state (Figure 3B).
Results of FUN 1-stained biofilms using CSLM indicate that the
biofilms formed in the CaBChip show spatial heterogeneity, with
regions of metabolically active cells interspersed within the
extracellular matrix (composed of collagen as the encapsulating
material and most likely also of exopolymeric material produced
by biofilm cells), which is not stained by the metabolic dye. The
thickness of the biofilm was estimated to be approximately 50 mm.
Thus, from the point of view of their morphological, structural and
architectural properties and despite several thousand-fold minia-
turization, the nano-scale biofilms formed on the CaBChip display
phenotypic characteristics that are comparable to C. albicans
biofilms formed using standard methodologies [34,35].
Figure 1. An overview of growth of fungal biofilms on glass substrates: preparation and characterization of the C. albicans biofilm
chip. (A) Schematic of attachment of collagen-encapsulated C. albicans biofilms to modified glass slides. Glass slides modified with APTES were
coated with PSMA and a suspension of C. albicans yeast cells in microbiological media and collagen as encapsulating material was spotted onto the
glass slides. (B) The optimal concentrations of growth media, inocula, collagen and PSMA that supported maximum biofilm yield in spots that also
attached robustly to substrate were obtained from a factorial design study. (C) A picture of the high-thoughput CaBChip, printed using a robotic
microarrayer and containing 768 spots on PSMA-coated slides. Each hemispherical spot is 50 nL in volume, approximately 700 mm in diameter, and
with a 1.2 mm separation between spots. Also shown is a fluorescent picture of fungal biofilms formed on the chip and stained with FUN 1, taken
with a microarray scanner, alongside a close-up image of nano-biofilms.
doi:10.1371/journal.pone.0019036.g001
High-Throughput Biofilm Chip
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and antifungal susceptibility testing
An important aspect of a high density array is the ability to
make multiple measurements at a single time. Thus, it is
imperative to demonstrate that all C. albicans biofilms formed in
a same CaBChip are equivalent to each other, which is essential for
its future use in large scale high throughput/high content
screening applications. To this end, we optimized the viability
stain FUN 1 and operating parameters of the microarray scanner
such that the fluorescence intensity correlated linearly with cell
number over the range of interest (Figure 4A). We also found that
the fluorescent intensities from spots that are seeded at same initial
cell density were statistically indistinguishable (P,0.05, Figure 4B)
indicating uniform distribution of biofilms at different locations on
the CaBChip. This demonstrates that the CaBChip is a valid
microarray-based platform for high-throughput screening tech-
niques, including drug discovery or the screening of large
collections of mutant strains, that will allow for the genetic
dissection of the biofilm developmental process [36].
From a clinical perspective, one of the main negative
consequences of biofilm formation is the high levels of antifungal
drug resistance against most clinically used antifungal agents
exhibited by C. albicans cells within biofilms [37]. This is one of the
major contributors to the unacceptably high morbidity and
mortality rates associated with candidiasis, despite of $3 billion
per year spent on antifungal medications in the US alone [38].
Thus, there is an urgent need for the development of new and
improved antifungal therapies, and the process of biofilm
formation represents a very attractive target. In order to ascertain
the functionality of CaBChip in determining the susceptibility
profiles of antifungal drugs against pre-formed biofilms, we carried
out antifungal susceptibility testing of 24 h C. albicans biofilms
grown on CaBChip against fluconazole and amphotericin B. Using
the robotic arrayer, drug concentrations of double-increments
were spotted on top of the mature pre-formed biofilms on
CaBChip and incubated for an additional 24 h period, after which
time FUN 1 was added. The fluorescence intensity of control (no
Figure 2. Kinetics of fungal biofilm formation on CaBChip. (A) Light microscopy: a series of microphotographs showing the formation of
nano-biofilms over time upon incubation at 37uC after initial printing using the robotic microarrayer. Magnification is6100 for all panels. (B) Growth
kinetics of C. albicans biofilm formation in CaBChip as determined using FUN 1 staining and a microarray reader. Cells were printed on the chips,
incubated at 37uC and fluorescence readings were taken over a 48 hour period. Results are expressed as arbitrary Relative Fluorescence Units (RFUs).
doi:10.1371/journal.pone.0019036.g002
Figure 3. Characterization of morphological and architectural
characteristics of fungal biofilms formed in CaBChip. (A) A series
of SEM images at increasing magnification (326, 2006, 1.4k6, 8.2k6
and 25.14k6)o fC. albicans nano-films formed in CaBChip after 24 h
incubation. Hyphae enmeshed in collagen fibers can be clearly seen at
the highest magnification. (B) Three-dimensional reconstruction of a
FUN 1-stained C. albicans 24 h nano-biofilm formed in CaBChip using
CSLM and the associated software for the compilation of xy optical
sections taken across the z axis.
doi:10.1371/journal.pone.0019036.g003
High-Throughput Biofilm Chip
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arbitrarily set at 100% and 0% respectively, and the inhibitory
effects of the antifungal agents were determined by the reduction
in fluorescence intensity in comparison to the controls. As in the
case of biofilms formed using regular methods (i.e. 96 well
microtiter plate model), we observed that the biofilms formed on
CaBChip were intrinsically resistant to fluconazole with SMIC50
and SMIC80 values of .1,024 mg/ml. From the corresponding
curve (Figure 5), the calculated IC50 for fluconazole was
.1,024 mg/ml. Since one of the main mechanisms of biofilm
Figure 4. Validation of the fungal biofilm chip for high-throughput analyses. (A) Correlation of fluorescence intensities of spots obtained
after FUN 1 staining with the number of viable cells present in each spot. The fluorescence intensities were measured using a microarray scanner and
the values are expressed as RFUs. (B) Fluorescence intensity of nano-biofilms on CaBChip stained with FUN 1. Values represent mean and standard
deviations of multiple independent biofilms formed in each of 9 different blocks of the chip.
doi:10.1371/journal.pone.0019036.g004
Figure 5. Dose-response curves of CaBChip after treatment with antifungal drugs. Results of antifungal susceptibility testing and
determination of IC50 values for fluconazole and amphotericin B using CaBChip.
doi:10.1371/journal.pone.0019036.g005
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compounds by beta-glucans in the extracellular matrix of the
biofilm [15,16,17,18,19,20], this provides additional evidence for
the production of exopolymeric material by cells within the
nanobiofilms. Also similar to regularly formed C. albicans biofilms,
amphotericin B was effective against biofilms formed on CaBChip,
but only at relatively high concentrations. From the corresponding
curve shown in Figure 5, the calculated IC50 for amphotericin B
was 0.2760.041 mg/ml, and the SMIC50 and SMIC80 values were
0.5 and 1 mg/ml, respectively. These results are consistent with
those previously reported for biofilms formed using conventional
techniques [22,23,34] (see also Figure S3 and Table S1) and once
again further corroborate that, despite a near 2,000-fold
miniaturization (compared to biofilms formed using the conven-
tional 96-well microtiter plate model), the nanoscale biofilms on
the CaBChip display phenotypic properties, including high levels
of antifungal drug resistance, that are similar to those formed using
standard techniques. We note that preliminary assessment of
echinocandin antifungals indicates low activity of these agents
against the nanobiofilms (not shown). Compounds of this class are
relatively highly protein bound [39] and it is possible that they
bind to the encapsulating collagen matrix leading to decreased
efficacy. We are further investigating these findings and testing a
number of non-protein matrices for a second generation biofilm
chip.
In summary, we have successfully developed a cell-based high
density microarray, CaBChip, for the formation of C. albicans
nano-biofilms. Besides providing cell-specific islands on the
substrate, the hydrophobic coating on the CaBChip allows for
an increased number of spots that could be printed in a
microscope slide. In addition, the choice of a suitable hydrogel,
as a ‘‘matrix’’ that encapsulates the individual biofilms, determines
the robustness of the chip. Maintaining the integrity of the gel and
controlling the adhesion of the matrix onto the substrate are
critical for the robustness and performance of the chip. Despite
nanoliter volume, the resulting biofilms demonstrate phenotypic
characteristics that are consistent with the C. albicans biofilm mode
of growth. The technology is flexible and we are currently
adapting it to other fungal and bacterial organisms. Thus, the
CaBChip is truly high-throughput: it employs nano-scale cultures,
enables rapid and easy handling, is amenable to automation and
fully compatible with standard microarray technology and
equipment. In its current format, a single CaBChip replaces up
to eight 96-well plates, and multiple chips can be printed and
processed simultaneously. By virtue of its miniaturization and
automation, the use of this technology platform minimizes manual
labor, cuts reagents use and drastically reduces assay costs. By
enabling rapid, convenient and inexpensive screening of hundreds-
to-thousands of compounds simultaneously, the use of CaBChip in
high-content screening applications has the potential for changing
the face of the antifungal drug discovery process.
Supporting Information
Methods S1 Factorial Designing of parameters for
biofilm growth and attachment on biofilms.
(DOCX)
Figure S1 Influence of experimental parameters on
biofilm yield and attachment. (A) Light microscopy and
FUN 1 staining shows that the biofilm yield is strongly dependent
on media and collagen concentration, and weakly on PSMA
coating concentration and initial seeding density; (B) Robust
attachment of spots was dependent on PSMA coating and collagen
concentration.
(TIF)
Figure S2 Interaction plot of design variables. Interaction
plots show the influence of different variables on two observed
outcomes: biofilm yield and robust attachment.
(TIF)
Figure S3 Dose-response curves of 96 well-plate assay
after treatment with antifungal drugs. Determination of
IC50 and SMIC50 and SMIC80 values for fluconazole and
amphotericin B using the 96-well microtiter plate model of C.
albicans biofilm formation, without (A) and with (B) collagen
encapsulation.
(TIF)
Table S1 IC50 in 96 well plate model. The IC50 values are
calculated from the dose-response curves of fluconazole and
amphotericin B against biofilms formed in a 96 well plate.
(TIF)
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